The Role of Moxifloxacin in Treatment of MDR Pulmonary Tuberculosis:a Prospective Randomized Preliminary Study.
- VernacularTitle:莫西沙星治疗耐多药肺结核近期疗效观察
- Author:
Peng XIAO
;
Zhiming MA
;
Hongmei FU
;
Al ET
;
- Publication Type:Journal Article
- Keywords:
Moxifloxacin;
Levofloxacin;
Muhidrugresistance;
Tuberculosis
- From:
Chinese Journal of Practical Internal Medicine
2006;0(S1):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the effectiveness of Moxifloxaein in treatment of multidrug-resistant(MDR)pulmonary tuberculosis.Methods 65 MDR pulmonary Mycobacterium tuberculosis patients were randomized divided into two groups,separately receiving the regimens of contained Moxifloxacin0.4 qd or Levofloxacin 0.6 qd six drugs treatment accompanying with aminoglycosides,prothionamide,pasiniazid,pyrazinamide,ethambutol and clarithromyein from 2003—2005y in Guangzhou chest hospital.The treatment outcomes were evaluated when study executed one and half year later.Results 35 patients in moxifloxacin group had 27 cases cured,and 30 patients in levofloxacin group had 19 cases cured.The success rates were 77.1% versus 63.3%(P=0.222).The time to sputum culture conversion were (1.9?0.7)months and 3.0?1.8 months(P=0.035).Bacillary susceptible to levofloxacin,good adherence,radi- ographic extent less than one lung,and use of moxifloxacin were independent predictors of favorable outcome(odds ratios,7.3 to 21.4).Conclusion Moxifloxacin was found have a better bactericidal activity in vivo and less side effects. Its efficacy was higher than levofloxacin when incorporated into muhidrug regimens used for treatment of MDR tuberculosis.
